388,355 Shares in Antares Pharma, Inc. (ATRS) Acquired by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC acquired a new position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 388,355 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,251,000. TIAA CREF Investment Management LLC owned about 0.25% of Antares Pharma as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of ATRS. Alliancebernstein L.P. purchased a new stake in Antares Pharma during the 2nd quarter worth approximately $119,000. Legal & General Group Plc purchased a new stake in Antares Pharma during the 2nd quarter worth approximately $120,000. Credit Suisse AG purchased a new stake in Antares Pharma during the 1st quarter worth approximately $146,000. National Planning Corp increased its holdings in Antares Pharma by 11.5% during the 2nd quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after purchasing an additional 6,000 shares during the last quarter. Finally, KCG Holdings Inc. increased its holdings in Antares Pharma by 48.8% during the 1st quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after purchasing an additional 21,881 shares during the last quarter. Institutional investors own 37.00% of the company’s stock.
A number of equities research analysts have recently weighed in on ATRS shares. Vetr upgraded Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target for the company in a report on Monday, July 24th. HC Wainwright set a $5.00 price target on Antares Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. ValuEngine downgraded Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. Antares Pharma has a consensus rating of “Buy” and an average target price of $3.84.
In related news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by insiders.
Shares of Antares Pharma, Inc. (ATRS) opened at $1.79 on Wednesday. Antares Pharma, Inc. has a twelve month low of $1.50 and a twelve month high of $4.09. The company has a current ratio of 3.47, a quick ratio of 3.04 and a debt-to-equity ratio of 0.61.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The business had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.01 million. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. equities research analysts anticipate that Antares Pharma, Inc. will post -0.11 EPS for the current fiscal year.
Antares Pharma Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.